Cellular and Molecular Immunology · 2020 · 47 citations · 6 references
Veterinary MedicineImmunologyInfectious DiseasesClinical ImmunologyInflammationSepsisBiomarkers In SepsisClinical Recognition Of SepsisImmune MonitoringImmunosuppressant MonitoringSepsis DiagnosisSepsis ManagementCritical Illness-associated ImmunodeficiencyImmune Biomarker MonitoringImmune Monitoring BiomarkersInfectious Disease Immune SurveillanceNatural Killer Cell MonitoringSepsis-associated InflammationSerologic Immune Monitoring
One of the immune characteristics of coronavirus disease 2019 (COVID-19) is a massive fall in lymphocyte count in which magnitude associates with mortality. 1 , 2 Recent monitoring of COVID-19 intensive care units (ICU) patients confirmed the profound lymphopenia and its remarkable stability over time. 3 , 4 While most immunomodulation approaches proposed so far in COVID-19 focused on inhibiting inflammatory cytokine response; mounting evidence indicates that this viral-induced defective lymphocyte response may play a central role in COVID-19 pathophysiology. 5 Interestingly, recombinant human interleukin-7 (IL-7) therapy, known to efficiently restore lymphocyte count in several viral infections was safely administered in septic shock patients 6 who present with similar lymphocyte alterations as observed in COVID-19. 3
6
Postmortem Examination of Patients With COVID-19
Tina Schaller, Klaus Hirschbühl, Katrin Burkhardt et al. · JAMA · 2020 · 589 citations · Full text
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial
Bruno François, Robin Jeannet, Thomas Daix et al. · JCI Insight · 2018 · 409 citations · Full text